Rajni K Jani

US Patent:

7977376, Jul 12, 2011

Filed:

Feb 7, 2007

Appl. No.:

11/703373

Inventors:

Onkar N. Singh - Arlington TX, US
G. Michael Wall - Fort Worth TX, US
Rajni Jani - Fort Worth TX, US
Masood A. Chowhan - Arlington TX, US
Wesley Wehsin Han - Arlington TX, US

Assignee:

Novartis AG - Basal

International Classification:

A61K 31/335

US Classification:

514450, 424810

Abstract:

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0. 6% (w/v) of olopatadine.

US Patent:

8399508, Mar 19, 2013

Filed:

Jun 30, 2011

Appl. No.:

13/173608

Inventors:

Onkar N. Singh - Arlington TX, US
G. Michael Wall - Fort Worth TX, US
Rajni Jani - Fort Worth TX, US
Masood A. Chowhan - Arlington TX, US
Wesley Wehsin Han - Arlington TX, US

Assignee:

Alcon Pharmaceuticals Ltd. - Fribourg

International Classification:

A61K 31/335

US Classification:

514450, 424810

Abstract:

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0. 6% (w/v) of olopatadine.

US Patent:

20040097474, May 20, 2004

Filed:

Nov 12, 2003

Appl. No.:

10/706759

Inventors:

Gerald Cagle - Fort Worth TX, US
G. Wall - Fort Worth TX, US
John Yanni - Burleson TX, US
Rajni Jani - Fort Worth TX, US
Haresh Bhagat - Fort Worth TX, US

Assignee:

Alcon, Inc.

International Classification:

A61K031/573
A61L009/04
A61K009/14

US Classification:

514/171000, 424/046000

Abstract:

Compositions and methods for treating rhinitis with certain combinations of antiallergic agents and steroids are disclosed.

US Patent:

20040167109, Aug 26, 2004

Filed:

Feb 5, 2004

Appl. No.:

10/772963

Inventors:

David Bingaman - Fort Worth TX, US
Abbot Clark - Arlington TX, US
Rajni Jani - Fort Worth TX, US
Stella Robertson - Fort Worth TX, US

International Classification:

A61K031/58
A61K031/573

US Classification:

514/176000, 514/179000

Abstract:

Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema.

US Patent:

20040171598, Sep 2, 2004

Filed:

Feb 4, 2004

Appl. No.:

10/771829

Inventors:

David Bingaman - Fort Worth TX, US
Abbot Clark - Arlington TX, US
Rajni Jani - Fort Worth TX, US
Stella Robertson - Fort Worth TX, US

International Classification:

A61K031/573

US Classification:

514/179000

Abstract:

Methods and compositions for treating retinal edema and NPDR are disclosed.

US Patent:

20050065137, Mar 24, 2005

Filed:

Sep 2, 2004

Appl. No.:

10/933006

Inventors:

Rajni Jani - Fort Worth TX, US
Ernesto Castillo - Arlington TX, US
Wesley Han - Arlington TX, US

International Classification:

A61K031/56

US Classification:

514171000

Abstract:

Injectable compositions of triamcinolone acetonide or anecortave acetate are disclosed. The compositions are particularly suitable for injection into the posterior segment of the eye to treat ophthalmic diseases.

US Patent:

20060074061, Apr 6, 2006

Filed:

Feb 5, 2004

Appl. No.:

10/545053

Inventors:

David Bingaman - Fort Worth TX, US
Abbot Clark - Arlington TX, US
Rajni Jani - Fort Worth TX, US
Stella Robertson - Fort Worth TX, US

International Classification:

A61K 31/573

US Classification:

514179000

Abstract:

Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema

US Patent:

20060141059, Jun 29, 2006

Filed:

Dec 23, 2005

Appl. No.:

11/317261

Inventors:

Masood Chowhan - Arlington TX, US
Ernesto Castillo - Arlington TX, US
Glenn Stafford - Burleson TX, US
Rajni Jani - Fort Worth TX, US
Haresh Bhagat - Fort Worth TX, US

International Classification:

A61K 31/7034
A61K 33/22

US Classification:

424660000, 514038000

Abstract:

Self-preserved, multi-dose ophthalmic compositions containing tobramycin are described. The compositions do not contain a conventional antimicrobial preservative, such as benzalkonium chloride. Rather, the compositions are self-preserved as a result of the inherent antimicrobial activity of tobramycin. The compositions preferably also contain either boric acid or, more preferably, a borate/polyol complex selected from the group consisting of borate/propylene glycol, borate/glycerol, and combinations thereof.